X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16) 16
humans (12) 12
oncology (12) 12
cancer (10) 10
middle aged (10) 10
adult (9) 9
aged (9) 9
chemotherapy (9) 9
female (9) 9
metastasis (8) 8
clinical trials (7) 7
patients (7) 7
survival (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
disease-free survival (6) 6
male (6) 6
treatment outcome (6) 6
tumors (6) 6
abridged index medicus (5) 5
aged, 80 and over (5) 5
cancer therapies (5) 5
medicine, general & internal (5) 5
melanoma (5) 5
metastases (5) 5
mutation (5) 5
antimitotic agents (4) 4
antineoplastic agents (4) 4
care and treatment (4) 4
deoxycytidine - administration & dosage (4) 4
deoxycytidine - analogs & derivatives (4) 4
double-blind (4) 4
drug administration schedule (4) 4
melanoma - drug therapy (4) 4
randomization (4) 4
risk factors (4) 4
survival analysis (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
breast neoplasms - drug therapy (3) 3
breast neoplasms - pathology (3) 3
capecitabine (3) 3
carboplatin (3) 3
cell lung-cancer (3) 3
cisplatin (3) 3
docetaxel (3) 3
drug therapy (3) 3
her2 (3) 3
imidazoles - administration & dosage (3) 3
kaplan-meier estimate (3) 3
kinases (3) 3
mek inhibitors (3) 3
multicenter (3) 3
nivolumab (3) 3
oximes - administration & dosage (3) 3
patient outcomes (3) 3
pembrolizumab (3) 3
pyridones - administration & dosage (3) 3
pyrimidinones - administration & dosage (3) 3
quinazolines - administration & dosage (3) 3
solid tumors (3) 3
therapy (3) 3
vemurafenib (3) 3
adjuvant chemotherapy (2) 2
analysis (2) 2
anemia (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
benzoates - administration & dosage (2) 2
blood platelets (2) 2
brain metastases (2) 2
breast cancer (2) 2
breast neoplasms - chemistry (2) 2
cancer research (2) 2
carcinoma (2) 2
clinical outcomes (2) 2
combination (2) 2
comparative analysis (2) 2
criteria (2) 2
deoxycytidine - adverse effects (2) 2
efficacy (2) 2
eltrombopag (2) 2
fluorouracil - administration & dosage (2) 2
fluorouracil - analogs & derivatives (2) 2
gemcitabine (2) 2
guidelines (2) 2
hematology, oncology and palliative medicine (2) 2
hydrazines - administration & dosage (2) 2
hypothyroidism (2) 2
imidazoles - adverse effects (2) 2
imidazoles - therapeutic use (2) 2
indoles - adverse effects (2) 2
indoles - therapeutic use (2) 2
intention to treat analysis (2) 2
interactive systems (2) 2
ipilimumab (2) 2
l-lactate dehydrogenase (2) 2
lactic acid (2) 2
lapatinib (2) 2
ligands (2) 2
lung cancer (2) 2
medical research (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1467 - 1482
Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess... 
CELL LUNG-CANCER | OVEREXPRESSION | AMPLIFICATION | ONCOLOGY | ONARTUZUMAB | ADENOCARCINOMA | HEPATOCYTE GROWTH-FACTOR | C-MET | RECEPTOR | AMG 102 | EXPRESSION | Capecitabine - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Stomach Neoplasms - pathology | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Esophageal Neoplasms - mortality | Adult | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Esophagogastric Junction - pathology | Proto-Oncogene Proteins c-met - drug effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Disease-Free Survival | Capecitabine - adverse effects | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Survival Analysis | Cisplatin - adverse effects | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Epirubicin - adverse effects | Clinical trials | Monoclonal antibodies | Anthracyclines | Product development | Esophageal cancer | Analysis
Journal Article
by Cohen, Ezra E W and Cohen, Ezra and Soulières, Denis and Le Tourneau, Christophe and Dinis, Jose and Dinis, José and Licitra, Lisa and Ahn, Myung-Ju and Soria, Ainara and Machiels, Jean-Pascal and Mach, Nicolas and Mehra, Ranee and Burtness, Barbara Ann and Burtness, Barbara and Zhang, Pingye and Cheng, Jonathan and Swaby, Ramona F and Harrington, Kevin and Harrington, Kevin J and Acosta-Rivera, Mirelis and Adkins, Douglas R and Aghmesheh, Morteza and Airoldi, Mario and Aleknavicius, Eduardas and Al-Farhat, Yousuf and Algazi, Alain P and Almokadem, Salah and Alyasova, Anna and Bauman, Jessica R and Benasso, Marco and Berrocal, Alfonso and Bray, Victoria and Caponigro, Francesco and Castro, Ana and Cescon, Terrence P and Chan, Kelvin and Chaudhry, Arvind and Chauffert, Bruno and Csoszi, Tibor and De Boer, J.P and Delord, Jean-Pierre and Dietz, Andreas and Dupuis, Charlotte and Digue, Laurence and Erfan, Jozsef and Escobar Alvarez, Yolanda and Evans, Mererid and Fidler, Mary Jo and Forster, Martin David and Friesland, Signe and Ganti, Apar K and Geoffrois, Lionnel and Grant, Cliona and Gruenwald, Viktor and Hoffmann, Thomas and Horvai, Geza and Inciura, Arturas and Jang, Raymond and Jankowska, Petra and Jimeno, Antonio and Joseph, Mano and Juarez Ramiro, Alejandro and Karaszewska, Boguslawa and Kawecki, Andrzej and Keilholz, Ulrich and Keller, Ulrich and Kim, Sung-Bae and Kocsis, Judit and Kotecki, Nuria and Kozloff, Mark F and Lambea, Julio and Landherr, Laszlo and Lantsukhay, Yuri and Lazarev, Sergey Alexandrovich and Lee, Lip Way and Lifirenko, Igor Dmitrievich and Martincic, Danko and Matorin, Oleg Vladmirovhich and McGrath, Margaret and Misiukiewicz, Krzysztof and Morris, John C and Mufazalov, Fagim Fanisovich and Niu, Jiaxin and Pamoorthy Srinivasan, Devraj and Perez Segura, Pedro and Rauch, Daniel and Ribeiro, Maria Leonor and Rodriguez, Cristina and Rolland, Frederic and Russo, Antonio and Ruzsa, Agnes and Sanches, Frederico and Shin, Sang-Won and Shtiveland, Mikhail and Soulieres, Denis and Specenier, Pol and Szekanecz, Eva and Szota, Judit and van Herpen, Carla M.L and Velez-Cortes, Hector A and ... and Keynote-040 Investigators and KEYNOTE-040 investigators
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 156 - 167
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2017, Volume 82, pp. 45 - 55
Journal Article
International Journal of Hematology, ISSN 0925-5710, 12/2017, Volume 106, Issue 6, pp. 765 - 776
Journal Article
by Mok, Tony and Mok, Tony S K and Wu, Yilong and Wu, Yi-Long and Kudaba, Iveta and Kowalski, Dariusz M and Kowalski, Dariusz and Cho, Byoung Chul and Turna, Hande and Turna, Hande Z and Castro, Hugo and Castro, Gilberto and Srimuninnimit, Vichien and Laktionov, Konstantin and Laktionov, Konstantin K and Bondarenko, Igor and Kubota, Kaoru and Lubiniecki, Gregory M and Zhang, Jin and Zhang, Li and Zhang, Xin and Kush, Debra and Lopes, Valeria and Lopes, Gilberto and Adamchuk, Grigory and Ahn, Myung-Ju and Alexandru, Aurelia and Altundag, Ozden and Alyasova, Anna and Andrusenko, Orest and Aoe, Keisuke and Araujo, Antonio and Aren, Osvaldo and Arrieta Rodriguez, Oscar and Ativitavas, Touch and Avendano, Oscar and Barata, Fernando and Barrios, Carlos Henrique and Beato, Carlos and Bergstrom, Per and Betticher, Daniel and Bolotina, Larisa and Botha, Michiel and Buddu, Sayeuri and Caglevic, Christian and Cardona, Andres and Cay Senler, Filiz and Cerny, Carlos Alexandre Sydow and Cesas, Alvydas and Chan, Gee-Chen and Chang, Jianhua and Chen, Xi and Chen, Gongyan and Cheng, Ying and Cheng, Susanna and Cherciu, Nelly and Chiu, Chao-Hua and Cicenas, Saulius and Ciurescu, Daniel and Cohen, Graham and Costa, Marcos Andre and Danchaivijitr, Pongwut and De Angelis, Flavia and de Azevedo, Sergio Jobim and Dediu, Mircea and Deliverski, Tsvetan and De Marchi, Pedro Rafael Martins and de The Bustamante Valles, Flor and Ding, Zhenyu and Doganov, Boyan and Dreosti, Lydia and Duarte, Ricardo and Edusma-Dy, Regina and Emelyanov, Sergey and Erman, Mustafa and Fan, Yun and Fein, Luis and Feng, Jifeng and Fenton, David and Fernandes, Gustavo and Ferreira, Carlos and Franke, Fabio Andre and Freitas, Helano and Fujisaka, Yasuhito and Galindo, Hector and Galvez, Christina and Ganea, Doina and Gil, Nuno and Girotto, Gustavo and Goker, Erdem and Goksel, Tuncay and Gomez Aubin, Gonzalo and Gomez Wolff, Luis and Griph, Hakan and Gumus, Mahmut and Hall, Jacqueline and Hart, Gregory and Havel, Libor and He, Yong and He, Jianxing and ... and KEYNOTE-042 Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10183, pp. 1819 - 1830
Journal Article